Nayanendu Saha

Title: Nayanendu Saha: Innovator in Cancer Diagnostics and Treatment

Introduction

Nayanendu Saha is a prominent inventor based in Jackson Heights, NY (US), known for his significant contributions to cancer diagnostics and treatment. With a total of three patents to his name, Saha has focused on developing innovative solutions that target specific cancer markers, enhancing the detection and treatment of various malignancies.

Latest Patents

Saha's latest patents include an anti-metalloprotease antibody designed for the diagnosis and treatment of cancers. This invention highlights the expression of proteolytically active, high molecular weight ADAM10 protease, which is relatively increased in tumor cells that also express the putative tumor stem cell marker CD133. The recombinant humanized antibody or antibody fragment based on the 8C7 monoclonal antibody can selectively bind to this protease, allowing for the detection of tumor cells. Additionally, this antibody serves as a therapeutic agent for treating a range of cancers, including leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumor, renal tumor, prostate cancer, sarcoma, and melanoma.

Career Highlights

Throughout his career, Nayanendu Saha has worked with esteemed institutions such as Beijing University of Technology and Memorial Sloan Kettering Cancer Center. His work in these organizations has contributed to advancements in cancer research and treatment methodologies.

Collaborations

Some of Saha's notable coworkers include Martin Lackmann and Peter W Janes, who have collaborated with him on various research projects aimed at improving cancer diagnostics and therapies.

Conclusion

Nayanendu Saha's innovative work in the field of cancer diagnostics and treatment exemplifies the impact of targeted therapies in modern medicine. His patents and collaborations continue to pave the way for advancements in cancer care, ultimately benefiting patients worldwide.